Avidity Biosciences (RNA) said Monday that topline data from the phase 1/2 EXPLORE44 trial of del-zota to treat Duchenne muscular dystrophy showed "consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase."
The biopharmaceutical company said del-zota also demonstrated favorable safety and tolerability in the dose cohorts. It also said it will present the data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference this week.
Shares of Avidity Biosciences were up 2.9% in recent premarket activity.
Price: 32.00, Change: +0.89, Percent Change: +2.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。